-
Cost of First-Line Treatment of Hepatocellular Carcinoma With the Immune Checkpoint Inhibitor-Based Regimens STRIDE and Atezolizumab Plus Bevacizumab in Brazil
Sep 9, 2025, 16:22 PM -
Data Linkage in Practice: A Living Systematic Review of Clinical Trials in the United States (US) Utilizing Linkage to Real-World Data
Sep 9, 2025, 16:22 PM -
Spain Leveling Up: A Comparison of Spain’s New National Health Economic Evaluation Guideline With Those of England, France, Germany, Italy, Portugal, Sweden, Ireland, Canada, Australia, and Japan
Sep 9, 2025, 16:22 PM -
Cardiovascular Effects of Semaglutide in Patients With Obesity, With or Without Type 2 Diabetes (T2DM): An Umbrella Review
Sep 9, 2025, 16:22 PM -
Science at PACE? A Multi-Stakeholder Developed Framework for Accelerated Patient Access to Cancer Care
Sep 9, 2025, 16:22 PM -
Accounting for the Additional Uncertainty Following Rank-Preserving Structural Failure Time Model (RPSFTM) Crossover Adjustment in Survival Analysis: A Sage Approach
Sep 9, 2025, 16:22 PM -
Patient Access Delays for Subsequent Indications of Multi-indication Treatments: An Assessment of Health Technology Assessment Decision Making
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of the 13-Valent Pneumococcal Conjugate Vaccine Compared With Higher-Valent Alternatives in the Pediatric Population of Paraguay
Sep 9, 2025, 16:22 PM -
Integrating CEUS in Diagnostic Pathways: Evidence of Economic and Organizational Sustainability From the Italian Healthcare System
Sep 9, 2025, 16:22 PM -
Quality of Life of Patients Living With Epilepsy in Hungary
Sep 9, 2025, 16:22 PM -
Costs and Health Outcomes of Meek Skin Micrografting vs. Mesh Skin Grafting in Adult Patients With Deep Partial Thickness and/or Full-Thickness Small (Burn) Wounds
Sep 9, 2025, 16:22 PM -
The Relationship Between Surrogate Endpoints and Overall Survival in Myelofibrosis Clinical Trials: Results From a Targeted Literature Review
Sep 9, 2025, 16:22 PM -
Evolution of Manufacturer-Set List Prices and GKV Rebates for Orphan Drugs (OD) in Germany 2013-2024: How Much US WAC Is in German OD-Prices
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Modifying Cardiovascular Disease Risk Factors in Qatar Using the Productivity-Adjusted Life Years (PALY) Metric
Sep 9, 2025, 16:22 PM -
The Clinical, Humanistic and Economic Burden of the Management of Patients With Recurrent Malignant Ascites in the UK and Europe
Sep 9, 2025, 16:22 PM -
How Can the Threshold Method Guide the Choice of Treatments? Illustration in French Patients With Hemophilia A or B
Sep 9, 2025, 16:22 PM -
Economic Burden of Systemic Lupus Erythematosus (SLE) Among Women in the USA: A Systematic Review
Sep 9, 2025, 16:22 PM -
Healthcare Resource Use and Mortality After Diabetic Ketoacidosis: Insights From Linked Primary- and Secondary-Care Data in the UK
Sep 9, 2025, 16:22 PM -
The Role of Lifestyle in the Development of Fertility Issues
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Control-IQ Hybrid Closed-Loop System in Adults With Type 1 Diabetes in Sweden
Sep 9, 2025, 16:22 PM
